Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictors of response to TNFα-blocking therapy in inflammatory bowel disease
2016-001278-13Phase 4Completed
- Sponsor
- Taina Sipponen
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by Taina Sipponen. Primary endpoints: Clinical induction response and Endoscopic induction response. Started Apr 2016; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2016-001278-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001278-13.